Gga (4160) reported revenue of NT$47.2 million for Oct 2026, +3.3% year on year and -2.0% from the previous month. Revenue for Jan–Oct 2026 was NT$505.9 million (+5.5% year on year).
Year-on-year revenue growth: 4 months in a row. →
In Oct 2026, it ranked No. 101 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$47.2 million | +3.3% | -2.0% |
| Sep 2026 | NT$48.2 million | +6.5% | -7.2% |
| Aug 2026 | NT$51.9 million | +11.5% | -11.8% |
| Jul 2026 | NT$58.9 million | +9.6% | +16.7% |
| Jun 2026 | NT$50.4 million | -0.5% | +7.0% |
| May 2026 | NT$47.2 million | +4.1% | -10.6% |
| Apr 2026 | NT$52.8 million | +7.5% | -18.5% |
| Mar 2026 | NT$64.7 million | +18.5% | +75.9% |
| Feb 2026 | NT$36.8 million | -21.9% | -23.2% |
| Jan 2026 | NT$47.9 million | +15.0% | -39.4% |
| Dec 2025 | NT$79 million | +32.9% | +77.7% |
| Nov 2025 | NT$44.5 million | -6.8% | -2.6% |
| Oct 2025 | NT$45.7 million | -4.8% | +1.0% |
| Sep 2025 | NT$45.2 million | -9.4% | -2.8% |
| Aug 2025 | NT$46.5 million | -19.7% | -13.4% |
| Jul 2025 | NT$53.7 million | -13.7% | +6.0% |
| Jun 2025 | NT$50.7 million | -5.7% | +11.9% |
| May 2025 | NT$45.3 million | -23.4% | -7.7% |
| Apr 2025 | NT$49.1 million | -13.5% | -10.1% |
| Mar 2025 | NT$54.6 million | -9.5% | +15.9% |
| Feb 2025 | NT$47.1 million | -0.1% | +13.1% |
| Jan 2025 | NT$41.6 million | -29.8% | -30.0% |
| Dec 2024 | NT$59.5 million | +4.6% | +24.6% |
| Nov 2024 | NT$47.7 million | -6.2% | -0.5% |
| Oct 2024 | NT$48 million | -4.0% | -3.9% |
Jan–Oct 2026 cumulative: NT$505.9 million (+5.5% YoY)
Other Biotech & Medical companies
Compare with peers: Gga vs PEC / Gga vs Lotus Pharm / Gga vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16